CD117 Protein - ACROBiosystems

CD117

CD117 Molecule Information

Name:Stem cell growth factor receptor
Target Synonym:Proto-oncogene c-Kit;CD_antigen=CD117;Tyrosine-protein kinase Kit;SCFR;Mast/stem cell growth factor receptor Kit;v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog;PBT;Piebald trait protein;p145 c-kit;KIT

Number of Launched Drugs:13
Number of Drugs in Clinical Trials:30
Lastest Research Phase:Approved

CD117 Protein Product ListCompare or Buy


CD7-H5255	Human	Human CD117 / c-kit Protein, Fc Tag
CD7-H52H4	Human	Human CD117 / c-kit Protein, His Tag

Cat. No.

Species

Product Description

Structure

Purity

Feature

CD7-H5255

Human

Human CD117 / c-kit Protein, Fc Tag

CD7-H52H4

Human

Human CD117 / c-kit Protein, His Tag

CD117 Molecule Synonym Name

CD117,SCFR,c-Kit,KIT

CD117 Molecule Background

Mast/stem cell growth factor receptor Kit (c-Kit), a member of the protein kinase superfamily, Tyr protein kinase family and CSF-1/PDGF receptor subfamily, is also known as piebald trait protein (PBT), p145 c-kit, tyrosine-protein kinase Kit and CD117,which contains five Ig-like C2-type (immunoglobulin-like) domains and one protein kinase domain. CD117 acts as cell-surface receptor for the cytokine KITLG/SCF and plays an essential role in the regulation of cell survival and proliferation, hematopoiesis, stem cell maintenance, gametogenesis, mast cell development, migration and function, and in melanogenesis. In response to KITLG/SCF binding, CD117 can activate several signaling pathways. Furthermore, Activated KIT promotes phosphorylation of the protein phosphatases PTPN6/SHP-1 and PTPRU, and of the transcription factors STAT1, STAT3, STAT5A and STAT5B.

CD117 References

CD117 Related Molecule

CD117 Public Drug Information

Name	Research Code	Research Phase	Company	First Brand Name	First Approved Country	First Indication	First Approved Company	First Approved Date	Indications	Clinical Trials
Anlotinib Dihydrochloride	AL-3818	Approved	Chiatai Tianqing (CTTQ), Advenchen Laboratories	Anlotinib Hydrochloride Capsules	cfda	Non small cell lung cancer (NSCLC), Soft tissue sarcoma, Small cell lung cancer (SCLC)		2018-05-08	Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), Soft tissue sarcoma	Details
Ancestim	AMJ-9302	Approved	Amgen, SOBI						Stem cell mobilization	Details
Imatinib mesylate	STI-571; CGP-57148B; CGP-57148; CTI-571; QTI-571,CGP57148B,STI 571,STI571,CGP 57148B	Approved	Novartis	GLEEVEC	fda	Gastrointestinal stromal tumors (GISTs), Chronic myeloid leukemia (CML )	NOVARTIS	2001-05-10	Myelodysplastic syndrome (MDS), Myeloproliferative Disorders (MPD), Gastrointestinal stromal tumors (GISTs), Aggressive systemic mastocytosis (ASM), Hypereosinophilic syndrome (HES), Dermatofibrosarcoma protuberans (DFSP), Chronic eosinophilic leukemia (CEL), Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML )	Details
Sorafenib Tosylate	BAY-54-9085; BAY-43-9006; BAY-43-0006; NSC-724772,BAY 43-9006,BAY54-9085,BAY43-9006,BAY 54-9085	Approved	Onyx Pharmaceutical, Bayer	NEXAVAR	fda	Differentiated thyroid cancer, Advanced renal cell carcinoma (RCC), Unresectable hepatocellular carcinoma	BAYER HLTHCARE	2005-12-01	Differentiated thyroid cancer, Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Unresectable hepatocellular carcinoma, Hepatocellular carcinoma (HCC)	Details
Regorafenib Monohydrate	BAY-73-4506; DAST,BAY73-4506,BAY 73-4506,BAY-734506	Approved	Bayer, Onyx Pharmaceutical	STIVARGA	fda	Gastrointestinal stromal tumors (GISTs), Metastatic colorectal cancer (CRC)	BAYER HLTHCARE	2012-09-27	Gastrointestinal stromal tumors (GISTs), Liver cancer, Metastatic colorectal cancer (CRC), Hepatocellular carcinoma (HCC)	Details
Pexidartinib	PLX-3397	Approved	Daiichi Sankyo	TURALIO	fda	Tenosynovial giant cell tumor (TGCT)	DAIICHI SANKYO INC	2019-08-02	Tenosynovial giant cell tumor (TGCT)	Details
Lenvatinib Mesylate	E-7080; ER-203492-00,E7080	Approved	Eisai	LENVIMA	fda	Thyroid cancer	EISAI INC	2015-02-13	Differentiated thyroid cancer, Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Thyroid cancer, Unresectable hepatocellular carcinoma, Hepatocellular carcinoma (HCC)	Details
Sunitinib Malate	PNU-290940; SU-11248; SU-010398; SU-011248-L-malate salt; PHA-290940; PHA-290940AD; PNU-290940AD; GB-102,SU11248,PNU 290940,PNU290940,SU 11248	Approved	Pfizer	SUTENT	fda		CPPI CV	2006-01-26	Renal cell carcinoma, Gastrointestinal stromal tumors (GISTs), Advanced renal cell carcinoma (RCC), Pancreatic neuroendocrine tumors (pNET), Renal carcinoma	Details
Ponatinib Hydrochloride	AP-24534; AP24534 HCl; AP24534 hydrochloride; AP24534-HCL; INCB-84344,AP 24534,AP24534	Approved	Ariad	ICLUSIG	fda	Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML )	ARIAD	2012-12-14	Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML )	Details
Avapritinib	BLU-285,BLU-285; CS-3007	Approved	Blueprint Medicines, CStone Pharmaceuticals	AYVAKIT	fda		BLUEPRINT MEDICINES CORP	2020-01-09	Gastrointestinal stromal tumors (GISTs)	Details
Cabozantinib S-malate	XL-184; BMS-907351,BMS907351,XL184,XL 184,BMS 907351	Approved	Exelixis, Ipsen, Takeda	COMETRIQ	fda	Medullary thyroid cancer (MTC)	EXELIXIS	2012-11-29	Renal cell carcinoma, Advanced renal cell carcinoma (RCC), Medullary thyroid cancer (MTC), Hepatocellular carcinoma (HCC)	Details
Pazopanib Hydrochloride	GW-786034; GSK-786034; GW-786034B ; SB-786034,GW786034,GW 786034	Approved	GlaxoSmithKline, Novartis	VOTRIENT	fda	Renal cell carcinoma, Soft tissue sarcoma	NOVARTIS	2009-10-19	Renal cell carcinoma, Soft tissue sarcoma, Soft tissue infections, Renal carcinoma	Details
Midostaurin	PKC-412; CGP-41231; CGP-41251; PKC-412A	Approved	Novartis	RYDAPT	fda	Systemic mastocytosis with associated hematological neoplasm, Aggressive systemic mastocytosis (ASM), Acute myeloid Leukemia (AML), Mast cell leukemia	NOVARTIS	2017-04-28	Systemic mastocytosis with associated hematological neoplasm, Aggressive systemic mastocytosis (ASM), Acute myeloid Leukemia (AML), Mast cell leukemia	Details
Dasatinib Hydrate	BMS-354825; NSC-732517 ,BMS354825,BMS 354825	Approved	Bristol-Myers Squibb	SPRYCEL	fda	Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML )	BRISTOL MYERS SQUIBB	2006-06-28	Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML )	Details

CD117 Clinical Drug Information

Name	Research Code	Research Phase	Company	Indications	Clinical Trials
Subutinib Maleate		Phase Ⅰ	Chiatai Tianqing (CTTQ), China State Institute of Pharmaceutical Industry (CSIPI)	Gastrointestinal stromal tumors (GISTs), Renal cell carcinoma, Breast cancer, Ovarian cancer, Pancreatic cancer	Details
PLX-9486	PLX-9486	Phase Ⅱ	Daiichi Sankyo	Gastrointestinal stromal tumors (GISTs), Solid tumours	Details
Anti-c-kit humanised IgG1/κ antibody-maitansine conjugate (Novartis)	LOP-628	Phase Ⅰ	Novartis	Solid tumours, Acute myeloid Leukemia (AML)	Details
Famitinib Malate	SHR-1020	Phase Ⅲ	Jiangsu Hengrui Medicine	Non small cell lung cancer (NSCLC), Colorectal cancer	Details
Vatalanib succinate	CGP-79787D; PTK-787; ZK-222584	Phase Ⅲ	Novartis, Bayer	Colorectal cancer	Details
Amuvatinib	MP-470; HPK-56,MP470,HPK56	Phase Ⅱ	Astex Pharmaceuticals	Small cell lung cancer (SCLC)	Details
SU-014813	SU-014813; SU-14813	Phase Ⅱ	Pfizer	Breast cancer	Details
Telatinib	BAY-57-9352; EOC-315	Phase Ⅱ	Bayer, Eddingpharm	Gastric cancer, Solid tumours	Details
Golvatinib/Lenvatinib		Phase Ⅱ	Eisai	Glioblastoma, Angiomas, Melanoma	Details
Tafetinib Malate	SIM-010603; SIM-0702; SIM-1005,SIM010603	Phase Ⅰ	Simcere, BolDere Pharma, Nanjing Yoko Biological	Colon cancer, Non small cell lung cancer (NSCLC), Gastrointestinal stromal tumors (GISTs), Renal cell carcinoma, Breast cancer, Liver cancer, Ovarian cancer	Details
Tandutinib	MLN-0518; MLN-518; CT-53518,MLN0518,MLN518,CT53518	Phase Ⅱ	Takeda	Renal cell carcinoma, Acute myeloid Leukemia (AML)	Details
QBH-196	QBH-196	Phase Ⅰ	Shenyang Pharmaceutical University	Gastric cancer	Details
Imatinib mesylate (YD Global Life Science)	YD-312	Phase Ⅱ	YD Global Life Science	Diabetic macular edema	Details
Dovitinib	CHIR-258; GFKI-258; CHIR-258LC; TKI-258; NVP-TKI258,GFKI258,CHIR258,TKI258	Phase Ⅲ	Novartis	Renal cell carcinoma, Solid tumours	Details
Motesanib Diphosphate	AMG-706,AMG706,AMG 706	Phase Ⅲ	Amgen, Takeda	Advanced non-squamous non small cell lung cancer (NSCLC)	Details
QLNC-3A6 Di-Maleate		Phase Ⅰ	Qilu Pharmaceutical, Qilu Antibiotics (Linyi) Pharmaceutical	Solid tumours	Details
Masitinib mesylate	AB-1010	NDA Filing	AB Science	Systemic mastocytosis with associated hematological neoplasm, Amyotrophic lateral sclerosis (ALS)	Details
AKN-028	AKN-028; BVT-II; BVT-63628 ,AKN028,BVTII,BVT63628	Phase Ⅱ	Akinion	Acute myeloid Leukemia (AML)	Details
IGN-311	IGN-311	Phase Ⅰ	PDL BioPharma, Celltrion	Cancer	Details
Hydroxychloroquine/Sorafenib		Phase Ⅰ	VG Life Sciences	Solid tumours, Ovarian cancer	Details
Donafenib Tosylate	CM-4307	Phase Ⅲ	Zelgen Biosciences	Thyroid cancer, Colorectal cancer	Details
FSI-174	FSI174,FSI-174	Preclinical	Forty Seven	hematological malignancies	Details
Sorafenib/MG-005	MGD-1509	Phase Ⅱ	Metagone Biotech, The General Hospital of the Three Armies	Solid tumours	Details
Thiophenib Tosylate	SIM-81; OSI-930	Phase Ⅰ	Astellas, Simcere	Small cell lung cancer (SCLC), Gastric cancer, Non small cell lung cancer (NSCLC), Colorectal neoplasms, Gastrointestinal stromal tumors (GISTs), Esophagus cancer, Ovarian cancer, Head and neck cancer, Malignant glioma	Details
Lapatinib/Pazopanib		Phase Ⅲ	GlaxoSmithKline	Renal cell carcinoma	Details
NMS-03592088	NMS-03592088; NMS-P088	Phase Ⅱ	Nerviano Medical Sciences	Acute myeloid Leukemia (AML), Chronic myeloid leukemia (CML )	Details
XL-820	XL-820	Phase Ⅱ	Exelixis	Gastrointestinal stromal tumors (GISTs)	Details
mSCF-based gene therapy (Celladon)		Preclinical	Celladon	ischaemic heart disorder	Details
Ripretinib	DCC-2618	NDA Filing	Deciphera, Zai Lab	Gastrointestinal stromal tumors (GISTs), Aggressive systemic mastocytosis (ASM), Malignancies	Details
AG-2034	AG-2034; AGL-2034	Phase Ⅰ	Yissum	Solid tumours	Details